Talo Labs

Talo Labs is a biotechnology company focused on the discovery and development of molecular glues to target "undruggable" proteins. Co-founded by chemical biology pioneer Stuart Schreiber and backed by F-Prime Capital, the company utilizes induced proximity to stabilize interactions between E3 ligases and disease-relevant targets. This approach facilitates the degradation or functional modulation of proteins that lack conventional small-molecule binding sites. Talo Labs' proprietary platform integrates advanced chemical biology and high-throughput screening to systematically identify novel glue degraders. The company's initial therapeutic focus is on oncology, aiming to provide new treatment options for patients with high unmet medical needs.